Skip to content
Winnowleaf home

Condition

Peripheral T-Cell Lymphoma

Peripheral T-cell lymphoma is a group of uncommon cancers in which mature T cells, immune white blood cells, grow out of control in lymph nodes and other tissues. The evidence is strongest for romidepsin, a drug, and trials in people whose lymphoma had returned or resisted earlier therapy found about a quarter to nearly 40 percent responded, across major subtypes. Those studies were moderate in size, and most people did not respond.

Sources: PMID 27981793

Supplements studied
0
Medicines and peptides
1
Graded outcomes
3
No supplement studies yetWe haven’t found supplement studies for Peripheral T-Cell Lymphoma. The medicines and peptides studied for it are listed below.

Prescription medicines and peptides studied, for context

These are not supplements. Most need a prescription, and some are research compounds with no approved use.

1 medicine or peptide

Romidepsin (Istodax)

Romidepsin (Istodax): outcomes studied for Peripheral T-Cell Lymphoma
GradeOutcomeEffectSizeStudiesPeopleStudies list
Overall Response Rate (PTCL)

Pivotal Phase 2 trial (n=130): ORR 25% with 15% CR/CRu. NCI multicenter study (n=47): ORR 38% with 17% CR. Responses seen across all major PTCL subtypes. Led to FDA approval June 2011.

Improves (the measure goes up)Moderate effect6 studies

Studies that measured overall response rate (ptcl)

and 3 more on the Romidepsin (Istodax) page

Duration of Response (PTCL)

Pivotal trial: Median DOR 28 months in responders. NCI trial: Median DOR 8.9 months (range 2-74 months). Durable responses possible in heavily pretreated patients (median 3 prior therapies).

Improves (the measure goes up)Large effect6 studies

Studies that measured duration of response (ptcl)

and 3 more on the Romidepsin (Istodax) page

Response by Prior Therapy

Responses observed regardless of number or type of prior therapies. Patients with up to 11 prior treatments responded. 38% of patients had prior stem cell transplant and still achieved responses.

Improves (the measure goes up)Moderate effect7 studies

Studies that measured response by prior therapy

and 4 more on the Romidepsin (Istodax) page

Key findings

  • Overall Response Rate (PTCL)Romidepsin (Istodax)Improves (the measure goes up)
  • Duration of Response (PTCL)Romidepsin (Istodax)Improves (the measure goes up)
  • Response by Prior TherapyRomidepsin (Istodax)Improves (the measure goes up)

Studies cited

8 studies from PubMed

  1. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.The Lancet. Haematology, 2024 · PMID 38796193
  2. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.The Lancet. Microbe, 2022 · PMID 35544074
  3. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Blood, 2021 · PMID 33171487
  4. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphomaCancer Med, 2017 · PMID 27981793
  5. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyJ Clin Oncol, 2012 · PMID 22271479
  6. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011 · PMID 21355097
  7. Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in females with a history of recurrent urinary tract infection: A 6-month multicenter, randomized, double-blind, placebo-controlled trial.Am J Clin Nutr · PMID 39863114
  8. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review.Front Nutr · PMID 39668896